The aim of this study was to examine the role played by substance P and calcitonin gene-related peptide (CGRP) within the dorsal horn of the spinal cord in engagement of antinociception evoked by dexmedetomidine (DEX). Paw withdrawal threshold (PWT) to mechanical stimulation was determined after chronic intrathecal infusion of DEX and enzyme-linked immunosorbent assay (ELISA) was employed to examine the levels of spinal substance P and CGRP. Our results show that PWT was significantly increased by intrathecal administration of DEX in rats (P < 0.05 vs. vehicle control, n = 20 in each group). Also, intrathecal infusion of DEX significantly decreased the concentrations of substance P and CGRP as compared with vehicle control (P < 0.05 DEX vs. vehicle control, n = 20 in each group). Blocking α 2 -adrenoreceptors (α 2 -AR) blunted the decreases of substance P and CGRP levels and the enhancement of PWT evoked by DEX. Additionally, a linear relationship was observed between PWT and the levels of spinal substance P (r = 0.87; P < 0.005) and CGRP (r = 0.85; P < 0.005). Moreover, blocking individual substance P and CGRP receptors amplified PWT without altering substance P and CGRP levels. Thus, DEX plays a role in stimulating α 2 -AR receptors, which thereby decreases substance P and CGRP levels within the dorsal horn. This contributes to DEX-evoked antinociception.
Introduction
Dexmedetomidine (DEX) is often used by intensive care units physicians and anesthesiologists because of its sedative effect on critically ill or injured patients [1, 2] . There are minimal contraindications to the use of DEX. This drug has recently been applied to non-intubated patients who require sedation for short-term surgeries or procedures [3] [4] [5] .
DEX is also useful as an adjunct for sedation and general anesthesia in the setting of certain operations and invasive medical procedures, such as colonoscopy [3] [4] [5] .
Similar to clonidine, DEX is an agonist of α 2 -adrenoreceptors (α 2 -AR) in the central nervous system, and both drugs have been used clinically for sedation and anesthesia [6] .
They have been administered through various approaches, including systemic, intrathecal, epidural, or peripheral perineural injections [7] .
In addition, prior studies have demonstrated that α 2 -AR are expressed in brainstem nuclei as well as in the superficial laminae of the spinal cord and primary afferent terminals [8] [9] [10] . These findings support the notion that DEX likely exerts an antinociceptive effect via α 2 -AR not only at the brainstem level, but also at the spinal and sensory nerve levels [11, 12] . Nevertheless, the precise mechanisms responsible for the antinociceptive effect of DEX at the spinal cord level require further investigation.
The superficial dorsal horn of the spinal cord is the first synaptic site for pain transmission from peripheral afferent nerves. In general, the levels of neurotransmitter release from the primary afferent nerve terminals into the dorsal horn play an important role in modulating pain [13] . Among many neurotransmitters, accumulated evidence suggests that substance P and calcitonin gene-related peptide (CGRP) within the superficial dorsal horn are particularly important for pain transmission to the central nervous system [13, 14] .
Therefore, in our current study, we first examined the effects of chronic intrathecal infusion of DEX on paw withdrawal threshold (PWT) to mechanical stimulation as well as the concentrations of substance P and CGRP within the dorsal horn of the spinal cord of rats.
We further examined if blocking α 2 -AR altered the PWT enhancement evoked by DEX and the levels of substance P and CGRP. A linear relationship was also analyzed between the levels of substance P/CGRP and PWT. Moreover, we examined if selectively blocking substance P, neurokinin 1 (NK-1) or CGRP receptors altered PWT and the levels of substance P and CGRP within the dorsal horn. We hypothesized that intrathecal administration of DEX stimulates In a subset of studies (n = 10 in each of following experiments), using the same methods, an osmotic mini pump was used to intrathecally deliver NK-1 receptor antagonist CP-96345 (300 nM, Pfizer Research, Groton, CT, USA) and CGRP antagonist CGRP 8-37 (2 mg/ml, Bachem, Torrance, CA, USA), respectively [17] .
These experiments were conducted to examine the pathways by which DEX acts.
The pump was designed to constantly deliver the vehicle or the antagonists at 1 μl/h for 7 days after an initial activation period of 4 hours inside the animal. Thus, the rats were allowed to receive the vehicle or the antagonists for 7 days following the procedure. Only animals that showed no evidence of neurological deficits after catheter implantation were used for this study.
The In the presence of a response, the filament of next lower force was applied. In the absence of a response, the filament of next greater force was applied. To avoid injury during testing, the cutoff strength of the von Frey filament was 15 g.
A tactile stimulus producing a 50% likelihood of withdrawal was determined using the "updown" method [18] . Each trial was repeated 2 times at approximately 2 min intervals. The mean value was used as the force to produce a withdrawal response. A total of three trials in each animal were performed and 10 min were allowed between two consecutive trials. An interval time of 10 min was selected since it was sufficient to obtain a recovery of PWT. All the studies were performed using blind testing.
To examine the levels of substance P and CGRP in the dorsal horn of the spinal cord, ELISA was used. Substance P was measured using a substance P ELISA kit following the manufacturer's instructions (Enzo Life Sci Inc., Farmingdale, NY, USA). Briefly, the diluted tissue supernatant (100 μl) was placed in a 96-well goat anti-mouse IgG-coated plate and incubated for 2 h. After incubation, the plate was washed using the provided washing buffer, and the color was developed by adding p-nitrophenyl phosphate (pNPP) (200 μl) substrate after 45 min and determined by an ELISA plate reader. The amount of substance P was calculated by using a substance P standard curve. In a similar way, the CGRP content of the samples (100 μl supernatant) was determined using a commercial CGRP ELISA kit (Cayman Chemical Co., Ann Arbor, MI, USA). In summary, the diluted samples were placed in a 96-well plate incubated with precoated anti-rat IgG antibody overnight, washed and developed, and quantified [19] .
All data were analyzed using a one-way Moreover, a linear regression for mechanical withdrawal thresholds and the levels of substance P and CGRP was analyzed. Figure 2A and B further demonstrates that there was a close relationship between the levels of spinal substance P and PWT (r = 0.87 and P < 0.01), and levels of CGRP and PWT (r = 0.85 and P < 0.01). Prior studies showed that the activation of α 2 -AR causes potassium efflux from Giprotein-gated potassium channels in neuronal cells and this results in hyperpolarization and suppressed neuronal firing [22, 27] . It has also been reported that activation of α 2 -AR by DEX results in G s -protein-mediated facilitation of acetylcholine release from the spinal dorsal horn synaptosomes in vitro [28, 29] . In addition, spinal α 2 -AR stimulation produces analgesia in animals with neuropathic pain, and this effect is blocked after inhibition of the brain-derived neurotrophic factor (BDNF) signaling pathway [30] . DEX can also inhibit glial cell hypertrophy in the spinal dorsal horn and activate the extracellular signal-regulated kinase (ERK) signaling pathway [31, 32] .
Evidence has further demonstrated synergistic interactions that result from co-application of DEX and opioids or local anesthetics. α 2 -AR are responsible for the analgesic function of DEX at systemic and regional levels [7] . Using acute and chronic rat pain models, studies have shown that the antinociceptive systemic synergism of opioids and DEX is mediated by peripheral mu (µ) and delta (δ) opioid receptors and α 2 -AR [1, 33, 34] . It has also been reported that a synergy between δ opioid receptors and α 2 -AR agonists inhibit the release of CGRP from the primary afferent nerve terminals [35] . Systemic administration of morphine also enhanced the analgesic effect of intrathecal DEX via up-regulation of α 2A , α 2B and α 2C -AR in the lumbar dorsal root ganglion and Intrathecal administration of antagonists to NK-1 (CP-96345, n = 10 at 300 nM) and CGRP receptors (n = 10, CGRP 8-37 at 2 mg/ml) significantly increased PWT as compared with only aCSF injection (n = 10) (A and B). However, the levels of substance P and CGRP within the dorsal horn were not significantly altered by blocking NK-1 and CGRP receptors (B and C). Data are expressed as mean ± standard deviation. *P < 0.05 vs. aCSF control. Legend: CGRP, calcitonin gene-related peptide; aCSF, artificial cerebrospinal fluid.
dorsal horn [36] . Consistent with these prior results [35] , we demonstrated the role played by CGRP in mediating the antinociceptive effects of DEX. 
